Blood test may spot hidden sarcoma signals

NCT ID NCT03818412

Recruiting now Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for cancer detection, treatment response, and disease tracking. The goal is to develop a less invasive way to follow the disease compared to repeated biopsies or scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to detect soft tissue sarcoma early, predict treatment response, and monitor for recurrence.
What could go wrong: This is a small, early-stage observational study focused on measuring a biomarker, not testing a treatment. The findings may not translate into a reliable clinical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma liposarcoma sarcoma soft tissue sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.